Advertisement

Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo

William Y Kim, Michal Safran, Marshall RM Buckley, Benjamin L Ebert, Jonathan Glickman, Marcus Bosenberg, Meredith Regan, William G Kaelin

Author Affiliations

  1. William Y Kim1,
  2. Michal Safran1,
  3. Marshall RM Buckley1,
  4. Benjamin L Ebert1,2,
  5. Jonathan Glickman3,
  6. Marcus Bosenberg4,
  7. Meredith Regan5 and
  8. William G Kaelin Jr*,1,6
  1. 1 Department of Medical Oncology, Dana‐Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
  2. 2 Broad Institute of MIT and Harvard, Cambridge, MA, USA
  3. 3 Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
  4. 4 Department of Pathology, University of Vermont, Burlington, VT, USA
  5. 5 Department of Biostatistics and Computational Biology, Dana‐Farber Cancer Institute, Boston, MA and Department of Medicine, Harvard Medical School, Boston, MA, USA
  6. 6 Howard Hughes Medical Institute, Chevy Chase, MD, USA
  1. *Corresponding author. Department of Medical Oncology, Dana‐Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, 44 Binney Street, Mayer 457, Boston, MA 02115, USA. Tel.: +1 617 632 3975; Fax: +1 617 632 4760; E-mail: William_kaelin{at}dfci.harvard.edu
View Full Text

You do not have access to the full text of this article, the first page of the PDF of this article appears below.

PDF extract preview

Subscribers, please sign in with your username and password.

Log in through your institution